Immunovant (IMVT) Q1 FY27 earnings call

Immunovant reported a quiet quarter, but highlighted significant upcoming catalysts, including the imminent potential launch of brexpiprazole in dermatomyositis. The company is preparing for a "jampacked second half" with multiple top-line data readouts and program updates across its pipeline, including NIU, PH-ILD, and DroTRA. Management emphasized a "slow and steady" launch approach for brexpiprazole DM to build a strong foundation for future indications, while also progressing litigation and capital return initiatives.